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Lipiddisordersareacommonclinicalchallengeinthewesterncountries.Inpatientswithdyslipemia(totalcholesterol>200mg/dl,
HDL cholesterol < 35mg/dl, LDL cholesterol > 130mg/dl and triglycerides > 150mg/dl) it is mandatory to normalize blood
pressure (<130/80mmHg) aswell to reduce LDL-Cvalues to normallevels by usingdrugs to inhibitofendogenousandexogenous
cholesterol, to decrease triglycerides, and increases HDL-C up to normal range. It is also essential to maintain for this purpose
suitable dietetic measures (reduction of unsatured fats and salt intakes—<2.5g/daily) and without interruption, to support
pharmacologictreatment in most of the patients.
1.Introduction
During many years I have been observing very often some
misunderstanding therapeutic ideas from several physicians
about the management of patients with lipid disorders
mostly in older hypertensive patients. This situation is
directly related to an insuﬃcient therapeutic control due to
inadequate drug dosages. However, we must not neglected
this point because good control is crucial for clinical point of
view and for the prognosis of the patients.
It is well established the relevance to provide some mea-
sures for the prevention and delay of atherosclerosis that is
closely related to the well-known cardiovascular risk factors,
such as, hypertension, smoking habit, dyslipemia, obesity,
diabetes, and many others disorders. On the other hand,
severe or fatal cardiovascular events related to the risk
factors are also important in order to oﬀer the patients a
bettermanagement to reducestroke,artery coronary disease,
peripheral arteriopathy, and other vascular diseases in west-
ern countries.
Hypertension, together with smoking habit and high
blood lipid levels, represents the most important pathogenic
cause for atherosclerosis and subsequent clinical severe dis-
eases.
The following ideas are based on my clinical experience
during many years on this particular clinical disorder.
Table 1: Levels of total cholesterol, triglycerides, HDL cholesterol,
and LDL cholesterol according to NECP Guidelines. Adult Panel III
(2002).
Cholesterol Goal
Ideal <200mg/dL
High limit 200–239mg/dL
High >239mg/dL
HDL cholesterol 40–55mg/dL
LDL cholesterol 50–130mg/dL
Triglycerides 50–150mg/dL
2.LoweringLipidLevels
As part of an overall strategy to stop atherosclerosis, control
of hypertension is very important (BP ≤ 140/80mmHg) in
all cases using general measures (diet, salt restriction, relief
of stress, regular aerobic exercise, and dietary management:
caloricrestriction, reduction ofcholesteroland saturated fats
i n t a k e )a sw e l la sd r u gt h e r a p yw h e nn e c e s s a r y[ 1]. Smoking
habit, for example, must be stopped as soon as possible, and
Current National Guidelines recommend having cholesterol
level screening in adults [2]. They also propose to obtain a
fasting lipid proﬁle (including total cholesterol, triglycerides,2 International Journal of Hypertension
Table 2: Drugs recommended to normaliselipid disorders.
Drugs to reduce LDL cholesterol
New statins
ACAT inhibitors
MTP inhibitors
Bile acids transport inhibitors
Speciﬁc cholesterol absorption inhibitors (Ezetimibe)
Drugs that increase HDL cholesterol
Nicotinic acid
PPAR α/β dual agonists
Lipoprotein lipase activators
CETP inhibitors
Drugs to treat Hypertriglyceridemia
Fibric acid derivatives
Icosapent ethyl ester
Doconexent ethyl ester
ACAT: Acyl-CoA cholesterol acyl transferase; MTP: microsomal triglyceride transfer protein; PPAR: proliferator-activated
receptor; CETP: cholesteryl ester transfer protein.
Table 3: NationalCholesterol Education Program. Therapeutic target according with the lipids blood levels.
Category of risk Target LDL-Ch LDL-Ch levels for no drugs LDL-Ch level for drug use
IC (risk to 10 years >20%) <100 ≥100 >130; 100–129 optional therapy
2+ risk factors, risk to 10 years (≤20%) <130 ≥130 Risk to 10 years 10–20% ≥130 risk 10
years <10% ≥160
0-1 risk factors <160 ≥160
≥190; 160–189 LDL-Ch optional lipid
drugs
IC: ischemic coronary disease.
LDL cholesterol, and HDL cholesterol) in patients with
known vascular diseases and those with several risk factors
or elevated total cholesterol levels.
3.SomeFrequentErrorsObservedin
the ClinicalPractice
Unfortunately, three types of mistakes are very common
present in clinical practice by many physicians: (1) some col-
leagues take as normal lipid values clearly high and neglect-
ing the reference values expressed on Table 1.A tt h i sp o i n t ,
many patients with moderately high cholesterol, triglyc-
erides, LDL-cholesterol and decreased HDL cholesterol with
values below ranging between 35 and 40mg/dL do not
receive any treatment; (2) it is well-known that statin/ﬁbrate
combination therapy is not recommended in same patient
to treat mixed dyslipemia; but unfortunaly, this procedure
is maintain by physicians in many cases. These associations
are not adequate because of their increasing side eﬀects
rhabdomyolysis, severe and even fatal in some patients; (3)
in my clinicalexperience, the most common error that I have
observed is the discontinuation of lipid lowering therapy
when normal values are reached; obviously expected, lipid
values become again pathologically high after suspension of
therapy (statins, ﬁbrates, or ezetimibe) (Table 2).
Nevertheles, thanks to the therapeutic arsenal available
today, observed normalization of lipid values in a large per-
centage of patients. The 4S study [3] demonstrated for
the ﬁrst time that intensive treatment to decrease lipid
levels achieved reduced mortality rate in patients with coro-
nary heart disease and cholesterol values between 212 and
309mg/dL (mean: 260mg/dL). The CARE study [4]s h o w e d
beneﬁcial eﬀects in patients with history of coronary heart
disease and total cholesterol of 175 to 240mg/dL (mean:
211mg/dL); the LIPID trial [5] showed an improvement in
total cardiovascular mortality rate with cholesterolemia lev-
els below those reported in the 4S study (mean: 220mg/dL).
The AFCAPS/TexCAPS study [6] showed the beneﬁt of
lipid-lowering treatment of cardiovascular morbidity and
mortality rate in primary prevention in individuals with
levels between 180 and 264mg/dL (mean, 221mg/dL) aged
45–75 years, as well as a slight decrease of HDL-C levels
in individuals with cholesterol values considered within
the normal limits (180–264mg/dL; mean: 221mg/dL). The
PROVE-IT [7] demonstrated that intensive lipid-lowering
therapy versus standard treatment reduced signiﬁcantly
cardiovascular morbidityand mortality rate after acutecoro-
nary syndromes.
These studies have cleared the way to recommend statins
therapy in patients treated for secondary prevention (high
risk) and primary prevention with other related risk factors
(Table 3).
Our experience demonstrated in hypertensive patients
older than 60 as the coadministration of ezetimibe/sim-
vastatin + fenoﬁbrate improved atherogenic lipid proﬁle
with mixed hyperlipidemia [8]. Another recent study, with
participation of my group [9] showed that the association of
“extended-released niacin and laropiprant (ERN/LRDT) +
statin” signiﬁcantly improved the lipid proﬁle compared toInternational Journal of Hypertension 3
the run-in dose doubled, and it was generally well tolerated
in patients with primary hypercholesterolemia and mixed
dyslipemia. The protocol was the following: after a 2- to 6-
week run-in statin (simvastatin 10 or 20mg or atorvastatin
10mg)period, 1216patientswererandomised equallytoone
of two treatment groups in a double-blind fashion: group
1 received ERN/LRPT (1g) plus the run-in statin dose and
advanced to ERN/LRPT (2g) after 4 weeks for an additional
8weeks, withnoadjustments totherun-in statindose;group
2 received simvastatin or atorvastatin at twice their run-in
statin dose and remained on this stable dose for 12 weeks.
Some of the molecules under study (clinical trials phase
II or III) in which our unit is participating actively are
expressed in Merck Pipeline: cardiovascular: MK-0736, MK
6621 (vernakalant),atherosclerosis MK-0524-A (tredaptive),
MK-0524B, and MK-0859 (anacetrapib).
In summary, treatment and control of arteriosclerotic
vascular disease in hypertensive patients needs the overall
treatment of the risk factors; in particular, in patients with
dyslipemia, it is necessary to normalize blood pressure, to
reduce LDL-C values to normal levels by the inhibition
of endogenous and exogenous cholesterol, as well as to
decrease triglycerides, and increase HDL-C levels, so that it
is essential to maintain dietetic measures (reduction of salt
and unsaturated fat intakes) and continuous pharmacologic
treatment in most of the patients.
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